Clinical Review

Recent developments

Blood transfusion medicine

BMJ 2002; 325 doi: 10.1136/bmj.325.7356.143 (Published 20 July 2002)
Cite this as: BMJ 2002;325:143

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Fiona Regan, honorary senior lecturer and consultant haematologist (fiona.regan@nbs.nhs.uk)a,
  2. Clare Taylor, consultant in haematology and transfusion medicineb
  1. a Hammersmith Hospitals NHS Trust, London W12 0HS
  2. b Royal Free Hampstead NHS Trust, London NW3 2QG
  1. Correspondence to: F Regan

    In the past few years there has been increasing concern about blood transfusion safety. Avoidable transfusion errors, mostly in patient identification, remain a serious cause of injury and death. There is also heightened awareness of the risk of transmission of viral and bacterial infections. Of particular concern in Britain is the (theoretical) possibility of transmission of variant Creutzfeldt-Jakob disease.

    This review puts these risks in perspective (table) and describes the new measures that have been introduced to improve blood safety. It also describes changes in attitude and practice that will affect users of blood in all disciplines, including general practitioners advising patients of the pros and cons of transfusion. Finally it emphasises the need for careful education and training of all those involved in blood prescribing and blood component administration.

    Summary points

    Human error is a cause of transfusion related morbidity and mortality: these errors are entirely avoidable

    The adoption of a lower “transfusion trigger” is gaining acceptance

    Whether or not variant Creutzfeldt-Jakob disease is transmissible by transfusion, it may have a considerable impact on availability of blood for transfusion

    Concerted efforts must now be made to reduce inappropriate blood use and to use alternatives and blood sparing agents

    Pilot studies of barcode patient identification systems are assessing their feasibility in various clinical settings

    Phase III clinical trials of blood substitutes (haemoglobin solutions and perfluorocarbons) are in progress

    View this table:
    • In this window
    • In a new window

    Risks of red blood cell transfusion (adapted from British Committee for Standards in Haematology (2001)1)

    Methods

    Our review is based on information from the annual reports of Serious Hazards of Transfusion (www.shot.demon.co.uk/), the guidelines of the British Committee for Standards in Haematology (www.bcshguidelines.com/), and the chief medical officer's second “Better Blood Transfusion” meeting (www.doh.gov.uk/bbt2). We also cite relevant recent publications by leading clinicians and scientists.

    New measures to reduce transfusion errors

    Avoidable transfusion errors remain an important if uncommon …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular